

Message

From: Shams, Dahnish [Shams.Dahnish@epa.gov]
Sent: 12/7/2021 3:18:09 PM
To: Cowen, Tracey [USA - EMP] [TCowen@versar.com]; Kapraun, Dustin [Kapraun.Dustin@epa.gov]
CC: Husain, Hassan [USA - EMP] [hhusain@versar.com]; Bogen, Kenneth [USA - EMP] [KBogen@versar.com]; Williams, Laura [USA - EMP] [lwilliams@versar.com]
Subject: RE: Peer Review of PBPK Modeling for Chloroprene Follow Up: Final Draft Comment Report

Thank you Tracey! Appreciate all your efforts on this peer review.

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Cowen, Tracey [USA - EMP] <TCowen@versar.com>
Sent: Monday, December 6, 2021 1:24 PM
To: Shams, Dahnish <Shams.Dahnish@epa.gov>; Kapraun, Dustin <Kapraun.Dustin@epa.gov>
Cc: Husain, Hassan [USA - EMP] <hhusain@versar.com>; Bogen, Kenneth [USA - EMP] <KBogen@versar.com>; Williams, Laura [USA - EMP] <lwilliams@versar.com>
Subject: Peer Review of PBPK Modeling for Chloroprene Follow Up: Final Draft Comment Report

Hi Dahnish and Dustin,

Please find attached the final draft comment report for a report on physiologically based pharmacokinetic (PBPK) modeling for chloroprene (Ramboll, 2021). Dr. Smith indicated that he had no additional edits to his review.

It has been a pleasure working with you on this review.

Thanks,
Tracey

Tracey L. Cowen
Environmental Scientist
Environmental Services Group



Direct: 301-304-3121
Mobile: Ex. 6 Personal Privacy (PP)
Email: tcowen@versar.com
Visit us at: www.versar.com

From: Shams, Dahnish <Shams.Dahnish@epa.gov>
Sent: Friday, December 3, 2021 4:46 PM
To: Cowen, Tracey [USA - EMP] <TCowen@versar.com>
Cc: Husain, Hassan [USA - EMP] <hhusain@versar.com>; Kapraun, Dustin <Kapraun.Dustin@epa.gov>
Subject: RE: Peer Review of PBPK Modeling for Chloroprene Follow Up: Revised Draft Report

Hi Tracey – Sorry for the delay here. I think we should be good to go to finalize this peer review. I haven't received any additional comments from the team and I think we should be good to go. Can you provide a finalized version of the document (assuming you've gotten no updates from Dr. Smith)?

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Cowen, Tracey [USA - EMP] <TCowen@versar.com>
Sent: Wednesday, November 17, 2021 11:02 AM
To: Shams, Dahnish <Shams.Dahnish@epa.gov>
Cc: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Subject: Peer Review of PBPK Modeling for Chloroprene Follow Up: Revised Draft Report

Hi Dahnish,


Please see attached the revised comment report. We contacted the reviewers to request that they review their written comments to confirm and where appropriate clarify their tiering. Drs. Hsieh and Portier have provided additional edits/tiering of their comments and these revisions have been incorporated into the draft report. Drs. Shao, Yang, and Zhu checked their comments and confirmed that they had no additional edits. Dr. Smith is currently unavailable. We have contacted his assistant but received no response to our inquiry.

Let us know if you have any questions or comments.

Thanks,
Tracey

Tracey L. Cowen
Environmental Scientist
Environmental Services Group



Direct: 301.304.3121
Mobile: 
Email: tcowen@versar.com
Visit us at: www.versar.com

From: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Sent: Wednesday, November 10, 2021 3:19 PM
To: Cowen, Tracey [USA - EMP] <TCowen@versar.com>
Subject: FW: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Can you reach out to the reviewers for a final confirmation on Dahnish's comment below?

"The EPA team has no comments, but however, do you mind asking the reviewers to take one more quick pass of their written comments to confirm and where appropriate clarify their tiering (e.g., Tier 1, Tier 2, Tier 3)? "

Hassan Husain

Senior Program Manager
Environmental Services Group



hhusain@versar.com

Direct Office: 240-252-2304

Mobile: Ex. 6 Personal Privacy (PP)

www.versar.com

From: Shams, Dahnish <Shams.Dahnish@epa.gov>
Sent: Wednesday, November 10, 2021 3:04 PM
To: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Hi Hassan – I just wanted to check on the chloroprene report. Any chance we can get the final report by the end of next week?

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Shams, Dahnish
Sent: Tuesday, November 2, 2021 4:09 PM
To: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Hassan – The EPA team has no comments, but however, do you mind asking the reviewers to take one more quick pass of their written comments to confirm and where appropriate clarify their tiering (e.g., Tier 1, Tier 2, Tier 3)?

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Sent: Tuesday, October 26, 2021 8:22 PM
To: Shams, Dahnish <Shams.Dahnish@epa.gov>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Dahnish,
Attached is the updated draft report and comment matrix. Let us know if you have any questions or comments as we get closer to the final report.

Hassan Husain
Senior Program Manager
Environmental Services Group



hhusain@versar.com

Direct Office: 240-252-2304

Mobile: Ex. 6 Personal Privacy (PP)

www.versar.com

From: Shams, Dahnish <Shams.Dahnish@epa.gov>
Sent: Tuesday, October 26, 2021 2:08 PM
To: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Ok thanks Hassan! Appreciate the quick response.

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Sent: Tuesday, October 26, 2021 1:59 PM
To: Shams, Dahnish <Shams.Dahnish@epa.gov>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Dahnish,
We got Dr. Smith's comments yesterday afternoon. We have incorporated the comments and are finalizing the report and matrix to send over to you. Should be there later today.

Hassan Husain
Senior Program Manager
Environmental Services Group



hhusain@versar.com

Direct Office: 240-252-2304

Mobile: Ex. 6 Personal Privacy (PP)

www.versar.com

From: Shams, Dahnish <Shams.Dahnish@epa.gov>
Sent: Tuesday, October 26, 2021 1:54 PM
To: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Hassan – Hope all is well. Quick question: do you have any updates on the final reviewers comments (Dr. Smith?)?

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA

O: (202) 564-2758

From: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Sent: Thursday, September 30, 2021 11:58 AM
To: Shams, Dahnish <Shams.Dahnish@epa.gov>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Dahnish,

Are you looking for reviewer attribution? There is a specific section at the back end that has each reviewers comments organized together, we could certainly put this in a table if that helps. Give me a call when you get a chance, happy to discuss further.

Hassan Husain
Senior Program Manager
Environmental Services Group



hhusain@versar.com
Direct Office: 240-252-2304
Mobile: Ex. 6 Personal Privacy (PP)
www.versar.com

From: Shams, Dahnish <Shams.Dahnish@epa.gov>
Sent: Wednesday, September 29, 2021 2:40 PM
To: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Hassan – Quick question: Is it possible to create a table at the front of the document that indicates which reviewers responded to each question? This would help us to review the document?

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Sent: Tuesday, September 21, 2021 9:03 PM
To: Shams, Dahnish <Shams.Dahnish@epa.gov>; Kapraun, Dustin <Kapraun.Dustin@epa.gov>
Cc: Cowen, Tracey [USA - EMP] <TCowen@versar.com>; Williams, Laura [USA - EMP] <lwilliams@versar.com>; Bogen, Kenneth [USA - EMP] <KBogen@versar.com>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Dahnish,

Draft report attached here. Let me know if you have any questions or need anything clarified. We will add in Dr. Smith's responses to this same report when we wrap that up

Hassan Husain
Senior Program Manager
Environmental Services Group

ED_006848_00000760-00005



hhusain@versar.com

Direct Office: 240-252-2304

Mobile: Ex. 6 Personal Privacy (PP)

www.versar.com

From: Shams, Dahnish <Shams.Dahnish@epa.gov>
Sent: Tuesday, September 21, 2021 10:16 AM
To: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

OK great! Thanks Hassan. We do need his comments by late October to make sure we have the final report in hand before responding to the RFC.

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Sent: Tuesday, September 21, 2021 10:10 AM
To: Shams, Dahnish <Shams.Dahnish@epa.gov>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Dahnish,
Will do, I can get that report into you today.
We'll also go ahead and get Dr. Smith initiated with the delivery date end of October.

Hassan Husain
Senior Program Manager
Environmental Services Group



hhusain@versar.com

Direct Office: 240-252-2304

Mobile: Ex. 6 Personal Privacy (PP)

www.versar.com

From: Shams, Dahnish <Shams.Dahnish@epa.gov>
Sent: Tuesday, September 21, 2021 9:44 AM
To: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Hi Hassan – Can we get the draft report without Dr. Smith's comments? We believe it might be too late for the RFC, but we would like his comments even if they come by late October.

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Sent: Monday, September 20, 2021 4:36 PM
To: Shams, Dahnish <Shams.Dahnish@epa.gov>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Yes we have responses from everyone else
I'll keep a lookout for your response re: Dr. Smith

Hassan Husain
Senior Program Manager
Environmental Services Group



hhusain@versar.com
Direct Office: 240-252-2304
Mobile: Ex. 6 Personal Privacy (PP)
www.versar.com

From: Shams, Dahnish <Shams.Dahnish@epa.gov>
Sent: Monday, September 20, 2021 4:31 PM
To: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Hi Hassan – See my responses in red below.

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Sent: Monday, September 20, 2021 4:23 PM
To: Shams, Dahnish <Shams.Dahnish@epa.gov>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Dahnish,
Original comment deadline was September 7th. Did we get responses from everyone else?
Dr. Zhu submitted his comments on Friday. We are wrapping up the draft compilation report and can get that over.
In regards to the final reviewer:

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Hassan Husain

Senior Program Manager
Environmental Services Group



hhusain@versar.com

Direct Office: 240-252-2304

Mobile: Ex. 6 Personal Privacy (PP)

www.versar.com

From: Shams, Dahnish <Shams.Dahnish@epa.gov>

Sent: Monday, September 20, 2021 4:17 PM

To: Husain, Hassan [USA - EMP] <hhusain@versar.com>

Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Hassan – What was the deadline for comments to be received from the reviewers?

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)

Center for Public Health and Environmental Assessment (CPHEA)

Office of Research and Development, U.S. EPA

O: (202) 564-2758

From: Husain, Hassan [USA - EMP] <hhusain@versar.com>

Sent: Wednesday, September 15, 2021 1:04 PM

To: Shams, Dahnish <Shams.Dahnish@epa.gov>; Kapraun, Dustin <Kapraun.Dustin@epa.gov>

Cc: Cowen, Tracey [USA - EMP] <TCowen@versar.com>; Williams, Laura [USA - EMP] <lwilliams@versar.com>; Bogen, Kenneth [USA - EMP] <KBogen@versar.com>

Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Dahnish,

I can talk after 3:30, I'll send you a Teams invite

Hassan Husain

Senior Program Manager
Environmental Services Group



hhusain@versar.com

Direct Office: 240-252-2304

Mobile: Ex. 6 Personal Privacy (PP)

www.versar.com

From: Shams, Dahnish <Shams.Dahnish@epa.gov>

Sent: Wednesday, September 15, 2021 11:47 AM

To: Husain, Hassan [USA - EMP] <hhusain@versar.com>; Kapraun, Dustin <Kapraun.Dustin@epa.gov>
Cc: Cowen, Tracey [USA - EMP] <TCowen@versar.com>; Williams, Laura [USA - EMP] <lwilliams@versar.com>; Bogen, Kenneth [USA - EMP] <KBogen@versar.com>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Hi Hassan – Can you talk at 2:30 PM ET today or after 3:30 PM ET?

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Sent: Tuesday, September 14, 2021 5:34 PM
To: Shams, Dahnish <Shams.Dahnish@epa.gov>; Kapraun, Dustin <Kapraun.Dustin@epa.gov>
Cc: Cowen, Tracey [USA - EMP] <TCowen@versar.com>; Williams, Laura [USA - EMP] <lwilliams@versar.com>; Bogen, Kenneth [USA - EMP] <KBogen@versar.com>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Dahnish,

Quick update on the candidates:

We continue to search for an in-vitro expert. To date we have contacted a total of 31 potential candidates for this expertise slot. At this point we are running into an issue of candidates with expertise are too closely related to the COI issues to be viable. I wanted to discuss with you further if you have some time Wednesday for a quick call.

On 9/3 we contacted the seven candidates listed below as well as sent a reminder earlier this week to those that hadn't replied yet:

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

The five selected reviewers are:

Nan-Hung Hsieh, Ph.D.

California Department of Pesticide Regulation

Expertise: PBPK modeling; Statistics; Global sensitivity analysis; Metabolic rates *in vitro*

Kenneth M. Portier, Ph.D.

Independent Consultant

Expertise: Statistics; PBPK modeling; Global sensitivity analysis

Kan Shao, Ph.D.

Indiana University

Expertise: Statistics; Global sensitivity analysis

Raymond S. H. Yang, Ph.D.

Colorado State University

Expertise: PBPK modeling

Yiliang Zhu, Ph.D.

University of New Mexico School of Medicine

Expertise: Statistics; Global sensitivity analysis

Hassan Husain

Senior Program Manager

Environmental Services Group



hhusain@versar.com

Direct Office: 240-252-2304

Mobile: Ex. 6 Personal Privacy (PP)

www.versar.com

From: Shams, Dahnish <Shams.Dahnish@epa.gov>

Sent: Tuesday, September 14, 2021 10:25 AM

To: Husain, Hassan [USA - EMP] <hhusain@versar.com>; Kapraun, Dustin <Kapraun.Dustin@epa.gov>

Cc: Cowen, Tracey [USA - EMP] <TCowen@versar.com>; Williams, Laura [USA - EMP] <lwilliams@versar.com>; Bogen, Kenneth [USA - EMP] <KBogen@versar.com>

Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Hassan – All the candidates should likely be considered if available. Since we've been specifically trying to find someone with in vitro ADME experience, EPA would lean towards those with that type of lab experience. Knowledge of PBPK is a definite plus, but they all seem to have some of that.

Ex. 5 Deliberative Process (DP)

Let us know if you have any additional comments on this and if you make a selection from the candidates below.

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Shams, Dahnish

Sent: Thursday, September 9, 2021 11:56 AM

To: Husain, Hassan [USA - EMP] <hhusain@versar.com>; Kapraun, Dustin <Kapraun.Dustin@epa.gov>

Cc: Cowen, Tracey [USA - EMP] <TCowen@versar.com>; Williams, Laura [USA - EMP] <lwilliams@versar.com>; Bogen, Kenneth [USA - EMP] <KBogen@versar.com>

Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Thanks Hassan! Let me huddle with the team.

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Husain, Hassan [USA - EMP] <hhusain@versar.com>

Sent: Thursday, September 9, 2021 11:05 AM

To: Shams, Dahnish <Shams.Dahnish@epa.gov>; Kapraun, Dustin <Kapraun.Dustin@epa.gov>

Cc: Cowen, Tracey [USA - EMP] <TCowen@versar.com>; Williams, Laura [USA - EMP] <lwilliams@versar.com>; Bogen, Kenneth [USA - EMP] <KBogen@versar.com>

Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Dahnish,
See below:

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Patrick Poulin, Ph.D.

Associate professor, School of Public Health, IRSPUM

patrick.poulin.4@umontreal.ca

<https://espum.umontreal.ca/lespum/equipe/personnel-enseignant/professeur/in/in21092/sg/Patrick%20Poulin/>

Université de Montréal, Canada, École de santé publique

7101, avenue du Parc

3e étage, bureau 3014-8

Montréal (Québec) H3N 1X9

Patrick obtained his doctorate in Public Health and a fellowship in pharmacology and toxicology. He is an independent consultant with qualifications in diverse aspects of health sciences and new medicines such as pharmaceuticals drug development, first-in-human (FIH) dose prediction for diverse therapeutic areas by using Physiologically-Based Pharmacokinetic (PBPK) modeling, in vitro-in vivo extrapolation (IVIVE), the Wajima allometric method, PKPD, computer modeling, medicinal chemistry, toxicological risk assessment, industrial medicine and hygiene, animal-alternative methods, and nutraceuticals as well as food Sciences and technology. Dr. Poulin has also since 2011 served as an associate professor at the University of Montréal, School of Public Health, Department of Occupational and Environmental Health, where he teaches and supervises scientific research by PhD students, and since 2012 as an expert reviewer for new drug submission and regulatory considerations in diverse therapeutic areas. Main specialties: Pharmacokinetics modeling (PK, PBPK, PK-PD, DMPK, Wajima Allometry, IVIVE, DDI, Drug Disposition, Tissue distribution, Pediatric PK, QSAR, Drug Discovery & Development), Computer modeling and simulation, Toxicology, Industrial medicine and hygiene, Reporting, Consulting, Teaching, Risk Assessment, Food Sciences, Audits, Expert reviews, Publications in scientific journals. One of Dr. Poulin's manuscripts was honored as the best publication of the year by the American Pharmacists Association and Journal of Pharmaceutical Sciences (i.e., Ebert Prize).

Ken-Ichi Umehara, Ph.D., Senior Principal Scientist

Investigative Safety, In vitro pharmacokinetics (PK) and drug-drug interaction (DDI) Section

Roche Pharmaceutical Research and Early Development, Roche Innovation Center

Grenzacherstrasse 124, CH-4070

Basel, Switzerland

kenichi.umehara@roche.com

Tel.: **Ex. 6 Personal Privacy (PP)**

At Roche since 2018, Dr. Umehara investigates DDI potential with in vitro tools, conducts PBPK modelling enable to propose more efficient strategy of clinical development, supports the M&S group from discovery to e.g. NDA submission/post-marketing. He previously worked for Novartis for 9 years, where he was responsible for conducting PBPK modeling to assess drug-drug interaction (DDI) potential of single agent or combination drug regimen, working with closely project teams, implemented PBPK models to avoid unnecessary *in vivo* studies, addressed drug labeling language, addressed questions from Health Authorities, implemented PBPK modeling to assess drug exposure in organ impairment populations and pediatrics to aid in clinical dosing regimen selection, and contributed to related publications.

Additionally, Dr. Smith responded and said he would be too busy until October but I think that may be too late for your timeline. We are still awaiting any response from the above folks.

Hassan Husain
Senior Program Manager
Environmental Services Group



hhusain@versar.com
Direct Office: 240-252-2304
Mobile: Ex. 6 Personal Privacy (PP)
www.versar.com

From: Shams, Dahnish <Shams.Dahnish@epa.gov>
Sent: Wednesday, September 8, 2021 12:02 PM
To: Husain, Hassan [USA - EMP] <hhusain@versar.com>; Kapraun, Dustin <Kapraun.Dustin@epa.gov>
Cc: Cowen, Tracey [USA - EMP] <TCowen@versar.com>; Williams, Laura [USA - EMP] <lwilliams@versar.com>; Bogen, Kenneth [USA - EMP] <KBogen@versar.com>
Subject: RE: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Hassan – Do you have any background information on the individuals below? Particularly, the pharma folks. Given that Yan and Ashton have declined, there is no need to provide information on them.

- Dahnish

Chemical & Pollutant Assessment Division (CPAD)
Center for Public Health and Environmental Assessment (CPHEA)
Office of Research and Development, U.S. EPA
O: (202) 564-2758

From: Husain, Hassan [USA - EMP] <hhusain@versar.com>
Sent: Tuesday, September 7, 2021 4:04 PM
To: Shams, Dahnish <Shams.Dahnish@epa.gov>; Kapraun, Dustin <Kapraun.Dustin@epa.gov>
Cc: Cowen, Tracey [USA - EMP] <TCowen@versar.com>; Williams, Laura [USA - EMP] <lwilliams@versar.com>; Bogen, Kenneth [USA - EMP] <KBogen@versar.com>
Subject: In-Vitro Update for Peer Review of PBPK Modeling for Chloroprene

Good afternoon Dahnish and Dustin,

I am writing to provide another update. We continue to search for an in-vitro expert. To date we have contacted a total of 31 potential candidates for this expertise slot. On Friday (9/3) we identified and contacted the seven additional candidates listed below:

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

We just wanted to run the names by you to perhaps get some initial insight on names that may raise COI flags or other issues. So far two people have declined (Drs. Ashton and Yan). The remaining candidates have not responded yet. In addition, we recontacted Dr. Jordan Smith from the original panel to ask if he would reconsider participating due to the timeline extension. He requested additional information regarding the level of effort and the new deadline; however, he has not responded after receiving that information.

Ex. 5 Deliberative Process (DP)

The five selected reviewers are:

Nan-Hung Hsieh, Ph.D.

California Department of Pesticide Regulation

Expertise: PBPK modeling; Statistics; Global sensitivity analysis; Metabolic rates *in vitro*

Kenneth M. Portier, Ph.D.

Independent Consultant

Expertise: Statistics; PBPK modeling; Global sensitivity analysis

Kan Shao, Ph.D.

Indiana University
Expertise: Statistics; Global sensitivity analysis

Raymond S. H. Yang, Ph.D.
Colorado State University
Expertise: PBPK modeling

Yiliang Zhu, Ph.D.
University of New Mexico School of Medicine
Expertise: Statistics; Global sensitivity analysis

As always let me know if you have any questions.

Hassan Husain
Senior Program Manager
Environmental Services Group



hhusain@versar.com
Direct Office: 240-252-2304
Mobile: Ex. 6 Personal Privacy (PP)
www.versar.com

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.

This email and any files transmitted with it are confidential and intended solely for the named addressee. This message contains confidential information and is intended only for the person so identified. If you are not the named addressee, you should not disseminate, distribute or copy this e-mail. If you received this message by mistake, please reply to this message and then delete it, so that we can ensure such a mistake does not occur in the future.
